Compugen (CGEN) Set to Post Quarterly Earnings on Monday

Compugen (NASDAQ:CGEN) is projected to post its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Compugen to announce earnings of ($0.08) per share and revenue of $1.28 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The firm had revenue of $2.60 million for the quarter, compared to analyst estimates of $1.28 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. On average, analysts expect Compugen to post ($0.28) EPS for the current fiscal year and ($0.20) EPS for the next fiscal year.

Compugen Price Performance

CGEN opened at $1.98 on Monday. The stock’s 50 day moving average price is $2.32 and its 200 day moving average price is $2.29. The stock has a market cap of $186.74 million, a P/E ratio of 5.21 and a beta of 2.85. Compugen has a 12 month low of $1.43 and a 12 month high of $3.23.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CGEN shares. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Compugen in a report on Monday, October 12th. Weiss Ratings raised shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Compugen presently has a consensus rating of “Buy” and a consensus target price of $5.00.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines.

Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.